DDInter740 DDInter1118
Flecainide is a Class I anti-arrhythmic agent like [encainide] and [propafenone]. Flecainide’s development began in 1966 and was first synthesized in 1972 as an attempt to generate new anesthetics. It is used to prevent supraventricular and ventricular arrhythmias, as well as paroxysmal atrial fibrillation and flutter.[L8878,L5056] Flecainide was granted FDA approval on 31 October 1985.
Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used commercially as a fire retardant. It can also be used topically as a deodorant or for the relief of canker sores (aphthous ulcers).
Flecainide {u} (Compound) resembles {v} (Compound) Mefloquine
Mefloquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium hydroxide
Flecainide {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Clozapine
Clozapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium hydroxide
Flecainide {u} (Compound) resembles {v} (Compound) Mefloquine
Mefloquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alimemazine
Alimemazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magnesium hydroxide
Flecainide {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Chlordiazepoxide
Chlordiazepoxide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magnesium hydroxide
Flecainide {u} (Compound) resembles {v} (Compound) Mefloquine
Mefloquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metoprolol
Metoprolol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magnesium hydroxide
Flecainide {u} (Compound) upregulates {v} (Gene) MTHFD2
MTHFD2 {u} (Gene) is upregulated by {v} (Compound) Sunitinib
Sunitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium hydroxide
Flecainide {u} (Compound) upregulates {v} (Gene) MTHFD2
MTHFD2 {u} (Gene) is downregulated by {v} (Compound) Digitoxin
Digitoxin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magnesium hydroxide
Flecainide {u} (Compound) upregulates {v} (Gene) HMOX1
HMOX1 {u} (Gene) is upregulated by {v} (Compound) Duloxetine
Duloxetine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magnesium hydroxide
Flecainide {u} (Compound) upregulates {v} (Gene) GARS
GARS {u} (Gene) is downregulated by {v} (Compound) Mycophenolic acid
Mycophenolic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium hydroxide
Flecainide {u} (Compound) downregulates {v} (Gene) RRM2
RRM2 {u} (Gene) is downregulated by {v} (Compound) Vemurafenib
Vemurafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium hydroxide
Flecainide (Compound) resembles Mefloquine (Compound) and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Flecainide (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Clozapine (Compound) and Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Flecainide (Compound) resembles Mefloquine (Compound) and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Flecainide (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Chlordiazepoxide (Compound) and Chlordiazepoxide may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Flecainide (Compound) resembles Mefloquine (Compound) and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Metoprolol and Metoprolol may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Flecainide (Compound) upregulates MTHFD2 (Gene) and MTHFD2 (Gene) is upregulated by Sunitinib (Compound) and Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Flecainide (Compound) upregulates MTHFD2 (Gene) and MTHFD2 (Gene) is downregulated by Digitoxin (Compound) and Digitoxin may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Flecainide (Compound) upregulates HMOX1 (Gene) and HMOX1 (Gene) is upregulated by Duloxetine (Compound) and Duloxetine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Flecainide (Compound) upregulates GARS (Gene) and GARS (Gene) is downregulated by Mycophenolic acid (Compound) and Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Flecainide (Compound) downregulates RRM2 (Gene) and RRM2 (Gene) is downregulated by Vemurafenib (Compound) and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide